Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$141.77 USD

141.77
186,425

+1.34 (0.95%)

Updated Sep 22, 2025 02:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Insulet Advances on Omnipod Reimbursement Update, Runs Risks

by Zacks Equity Research

Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.

    Zacks Equity Research

    Here's Why You Should Hold on to Align Technology (ALGN) Now

    by Zacks Equity Research

    Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.

      Zacks Equity Research

      Here's Why You Should Invest in Masimo (MASI) Right Now

      by Zacks Equity Research

      A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.

        Zacks Equity Research

        ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio

        by Zacks Equity Research

        ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.

          Zacks Equity Research

          QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers

          by Zacks Equity Research

          Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.

            Zacks Equity Research

            Cooper's MiSight Lens Effective in Checking Juvenile Myopia

            by Zacks Equity Research

            Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.

              Zacks Equity Research

              Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

              by Zacks Equity Research

              Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

                Zacks Equity Research

                CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise

                by Zacks Equity Research

                A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.

                  Zacks Equity Research

                  QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio

                  by Zacks Equity Research

                  QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.

                    Zacks Equity Research

                    DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand

                    by Zacks Equity Research

                    DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.

                      Zacks Equity Research

                      Omnicell Continues to Pursue Buyouts, Costs on the Rise

                      by Zacks Equity Research

                      Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.

                        Zacks Equity Research

                        AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology

                        by Zacks Equity Research

                        AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.

                          Zacks Equity Research

                          Cardiovascular Systems Portfolio Strong, Competition Rife

                          by Zacks Equity Research

                          Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.

                            Zacks Equity Research

                            Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel

                            by Zacks Equity Research

                            Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.

                              Zacks Equity Research

                              DENTSPLY Launches Azento, Improves Digital Implant Workflow

                              by Zacks Equity Research

                              DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.

                                Zacks Equity Research

                                Here's Why You Should Invest in Penumbra (PEN) Stock Now

                                by Zacks Equity Research

                                The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.

                                  Zacks Equity Research

                                  Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio

                                  by Zacks Equity Research

                                  IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.

                                    Nabaparna Bhattacharya headshot

                                    Allscripts' Sunrise Abstracting Selected by Wyckoff Heights

                                    by Nabaparna Bhattacharya

                                    Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.

                                      Zacks Equity Research

                                      Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT

                                      by Zacks Equity Research

                                      Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.

                                        Zacks Equity Research

                                        Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio

                                        by Zacks Equity Research

                                        A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.

                                          Zacks Equity Research

                                          Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio

                                          by Zacks Equity Research

                                          Stryker (SYK) on an acquisition spree; latest buyout likely to aid its array of surgical instruments.

                                            Zacks Equity Research

                                            Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?

                                            by Zacks Equity Research

                                            Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.

                                              Zacks Equity Research

                                              Here's Why You Should Hold On to DaVita (DVA) Stock Now

                                              by Zacks Equity Research

                                              Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.

                                                Zacks Equity Research

                                                Integra Lifesciences Picked for Healogics iSupply Program

                                                by Zacks Equity Research

                                                Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.

                                                  Zacks Equity Research

                                                  Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals

                                                  by Zacks Equity Research

                                                  Varian's (VAR) advanced cancer care solution prospects bright in the global market.